Patients’ characteristics
| N° (%) | |
|---|---|
| 976 | |
| AGE, (years) | |
| Median | 68 |
| Range | 24–92 |
| Elderly (≥ 70) | 445 (45.6) |
| SEX | |
| Male | 663 (67.9) |
| Female | 313 (32.1) |
| ECOG PS | |
| 0–1 | 831 (85.1) |
| ≥ 2 | 145 (14.9) |
| Primary Tumor | |
| NSCLC | 635 (65.1) |
| Melanoma | 183 (18.7) |
| Renal cell carcinoma | 135 (13.8) |
| Others | 23 (2.4) |
| No. of metastatic sites | |
| ≤ 2 | 467 (47.9) |
| > 2 | 509 (52.1) |
| Type of anti-PD-1/PD-L1 agent | |
| Pembrolizumab | 235 (24.1) |
| Nivolumab | 706 (72.3) |
| Atezolizumab | 35 (3.6) |
| Treatment line of Immunotherapy | |
| First | 260 (26.6) |
| Non-First | 716 (73.4) |
| Weight (Kg) | |
| Median | 71 |
| Range | 35–139 |
| BMI (kg/m2) | |
| Median (range) | 24.9 (13.5–46.6) |
| Underweight (BMI ≤ 18.5), n°(%) | 40 (4.1) |
| Normal weight (BMI 18.5 < BMI ≤ 24.9), n°(%) | 452 (46.3) |
| Overweight (25 < BMI ≤ 29.9), n°(%) | 377 (38.6) |
| Obese (BMI ≥ 30), n° (%) | 107 (11) |